Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,658 across all filing types
Latest filing 2020-08-26 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
2020年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "深圳信立泰药业股份有限公司 2020 年半年度报告全文" which translates to "Shenzhen Salubris Pharmaceuticals Co., Ltd. 2020 Semi-Annual Report Full Text." It contains detailed financial data, business overview, management discussion and analysis, R&D progress, and other comprehensive information typical of an interim or quarterly report. The document length is about 15,000 characters, indicating a full report rather than a brief announcement. The content includes financial figures for the half-year period, detailed business and operational analysis, and forward-looking statements. This matches the definition of an Interim / Quarterly Report (IR). H1 2020
2020-08-26 Chinese
2020年半年度报告摘要
Interim / Quarterly Report Classification · 100% confidence The document is titled "深圳信立泰药业股份有限公司 2020 年半年度报告摘要" which translates to "Shenzhen Salubris Pharmaceuticals Co., Ltd. 2020 Semi-Annual Report Summary." It contains detailed financial data, operating results, business analysis, accounting policy changes, and other substantive financial information for the half-year period of 2020. The document is over 10,000 characters long, indicating it is a full report rather than a brief announcement. The content includes financial metrics, shareholder information, R&D progress, and management discussion, all typical of an Interim / Quarterly Report. There is no indication that this is an Annual Report (10-K) or a simple announcement. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2020
2020-08-26 Chinese
独立董事关于公司有关事项所发表的独立意见
Audit Report / Information Classification · 95% confidence The document is a statement from independent directors regarding the company's external guarantees and related party fund occupation, referencing compliance with Chinese company law and stock exchange rules. It includes detailed opinions on the company's risk control measures, guarantees provided to subsidiaries, and confirms no violations or irregularities up to June 30, 2020. The document is signed by independent directors and dated August 25, 2020. It does not contain full financial statements or comprehensive financial performance data, nor is it a brief announcement or a certification letter. Instead, it is a specialized independent opinion report related to audit and compliance matters concerning guarantees and related party transactions. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles or regulatory compliance opinions, excluding full annual reports. H1 2020
2020-08-26 Chinese
关于部分药品拟中选全国药品集中采购的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the company's participation and proposed selection in a national centralized drug procurement organized by a government procurement office. It details the products involved, pricing, supply regions, and procurement terms. The document is a formal public announcement about a business development related to product procurement and market expansion, not a financial report, earnings release, or regulatory filing. It does not contain financial statements, management discussion, or voting results. It is also not a report publication or certification. The content fits best under a general regulatory announcement category that covers miscellaneous company disclosures that do not fit other specific categories.
2020-08-21 Chinese
关于获得盐酸帕罗西汀肠溶缓释片药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the receipt of a drug registration certificate for Paroxetine Hydrochloride Enteric-coated Sustained-release Tablets. It includes details about the drug, regulatory approval, market context, and potential impact on the company. The document is short (1115 characters) and serves as an official announcement of a regulatory approval event rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or management changes. It is not a report publication announcement since it does not mention the release of a report but rather announces a regulatory approval. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2020-08-17 Chinese
关于回购公司股份的进展公告
Transaction in Own Shares Classification · 95% confidence The document is titled as an announcement regarding the progress of the company's share repurchase program. It details the number of shares repurchased, prices, compliance with regulations, and other procedural information about the share buyback. It does not contain financial statements or earnings data but focuses on the company's transactions in its own shares. The document length is about 2000 characters, which is relatively short and consistent with an announcement rather than a full report. The content matches the description of a 'Transaction in Own Shares' filing, which reports on share repurchase activities.
2020-08-04 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.